IP Library Granted Patent US 10,100,307
Granted Patent B2
US 10,100,307 · App. 15/520,926 · Granted Oct 16, 2018

Use of a reverse-transcriptase inhibitor in the prevention and treatment of degenerative diseases

Inventors: Alain Prochiantz (Paris, FR); Julia Fuchs (Pantin, FR); Rajiv Joshi (Massy, FR); François Xavier Blaudin De The (Paris, FR); Hocine Rekaik (Melun, FR); Olivia Massiani-Beaudoin (Montgeron, FR)
Assignees: Centre National de la Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale (INSERM); College de France; Sorbonne Universite
C12N15/113C12N15/63C12Q1/25C12Q1/68C12N2740/00011
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,100,307
App. No.
15/520,926
Granted
Oct 16, 2018
Kind
B2
Abstract

The invention relates to the use of a reverse-transcriptase inhibitor in the prevention or treatment of a degenerative disease.

Claims (9)

1. A method of treating or preventing a degenerative disease in a subject in need thereof, the method comprising administering a therapeutically effective amount of a reverse transcriptase inhibitor to the subject, said degenerative disease being selected from the group consisting of Parkinson's disease, Alzheimer's disease, Huntington's disease, a degenerative disease affecting eyesight and a degenerative disease affecting hearing.

2. The method of claim 1 , wherein the reverse transcriptase inhibitor is a nucleoside inhibitor.

3. The method of claim 2 , wherein the degenerative disease is linked to aging or oxidative stress.

4. The method of claim 1 , wherein the degenerative disease affecting eyesight is glaucoma.

5. The method of claim 1 , wherein the degenerative disease is Parkinson's disease.

6. The method of claim 1 , wherein the degenerative disease is Alzheimer's disease.

7. The method of claim 1 , wherein the degenerative disease is Huntington's disease.

8. The method of claim 1 , wherein the degenerative disease is a degenerative disease affecting eyesight.

9. The method of claim 1 , wherein the degenerative disease is a degenerative disease affecting hearing.

Assignments (5)
CHANGE OF NAME Recorded Aug 1, 2018
From: UNIVERSITE PIERRE ET MARIE CURIE
To: SORBONNE UNIVERSITE
Reel/Frame 046522/0971 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: FUCHS, JULIA
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Reel/Frame 042250/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: PROCHIANTZ, ALAIN; BLAUDIN DE THE, FRANCOIS XAVIER
To: COLLEGE DE FRANCE
Reel/Frame 042250/0277 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: REKAIK, HOCINE
To: UNIVERSITE PIERRE ET MARIE CURIE
Reel/Frame 042415/0282 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2017
From: JOSHI, RAJIV; MASSIANI-BEAUDOIN, OLIVIA
To: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Reel/Frame 042415/0393 →
Priority Claims (1)
FR 14 60535 · Oct 31, 2014 · national
Continuity (1)
Related Publication 20170335320A1 · Nov 23, 2017
Cited By (4)
US 12,187,758 US 12,246,022 US 12,350,264 US 12,403,138